Agomab Therapeutics NV (“Agomab”) today announced late-breaking interim data from the ongoing STENOVA 1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule ...

In one patient, active mucosal involvement was present at the time of evaluation. In the ileum, complete healing occurred in 7/13 (54%) patients with ileitis, near-complete healing in 2/13 (15% ...

and friability of the ileocecal valve (Figure 1); the terminal ileum could not be intubated. Biopsies of the rectum and colon demonstrated a dense mucosal infiltrate of immature monocytes and ...

There are two main forms: Crohn s disease, which can affect the entire gastrointestinal tract, but is most common in the colon and terminal ileum; and ulcerative colitis, which is a mucosal ...

“The upper section is lined with squamous mucosa, which doesn’t have this ... The small intestine consists of the duodenum, ...

Objective Although immunoglobulin A (IgA) is abundantly expressed in the gut and known to be an important component of mucosal barriers against luminal pathogens, its precise function remains unclear.

Vedolizumab is a humanized monoclonal antibody that selectively targets the alpha4beta7 integrin, blocking its interaction with mucosal addressin ... the terminal ileum and colon.

Secondary endpoints include pharmacokinetics and target engagement as measured through transcriptomics in mucosal biopsies collected ... to AGMB-129 in the ileum but no clinically relevant ...

Results: In vivo, LL-37 expression in healthy mucosa was restricted to differentiated epithelial cells in human colon and ileum. In colonocytes, increased LL-37 expression associated with cell ...

Within our gut live trillions of microorganisms, mostly in the form of dense, organized communities along the intestinal ...

Effective mucosal immunity in the intestine involves a fine balance between tolerance of the microbiome, recognition and elimination of pathogens, and inflammatory tissue injury. The anti-inflammatory ...